Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Endeavor Biomedicines, Inc.
Eli Lilly and Company
Milton S. Hershey Medical Center
City of Hope Medical Center
National Cancer Institute (NCI)
Dana-Farber Cancer Institute
Istari Oncology, Inc.
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
Masonic Cancer Center, University of Minnesota
Washington University School of Medicine
Children's Oncology Group
National Cancer Institute (NCI)
Wake Forest University Health Sciences
Wake Forest University Health Sciences
Oncurious NV
Case Comprehensive Cancer Center
Lumos Pharma
Emory University
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
University of California, San Francisco
Medical College of Wisconsin
Stanford University
City of Hope Medical Center
Pediatric Brain Tumor Consortium
Wake Forest University Health Sciences
Novartis
Children's Oncology Group
University of Iowa
Memorial Sloan Kettering Cancer Center
University Hospital, Montpellier
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Duke University
Indiana University
Duke University
Children's Oncology Group
Duke University
National Cancer Institute (NCI)
INSYS Therapeutics Inc
Children's Oncology Group
University of South Florida
University of Pittsburgh
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)